Targeting PGK1 to enhance ferroptosis in breast cancer (AACR 2025) - Mar 26, 2025 - Abstract #1615; Pres time: Apr 28, 2025; 09:00 AM - 12:00 PM; Location: Section 17; Poster Board No: 2; "Notably, depletion of PGK1 sensitized TNBC cells to ferroptotic cell death induced by erastin, an activator of ferroptosis, and decreased colony formation and attenuated migratory ability of tumor cells...Furthermore, we demonstrated that the glycolytic inhibitor, sodium dichloroacetate (DCA), enhanced ferroptosis, while the glycolysis inducers such as hypoxia and oligomycin reduced ferroptotic cell death, in the tumor cells subjected to PGK1 depletion...This study demonstrates that PGK1 inhibition can attenuates GPX4, elevate pyruvate dehydrogenase expression, and cause a metabolic shift, thereby sensitizing tumor cells to ferroptosis induction. Thus, PGK1 may be exploited as a therapeutic target for overcoming ferroptosis resistance in breast cancer."
Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ACSL4 • GPX4 • PGK1 • TFRC
|
|
Felix F. Oyelami; Andrew T. Shinkle; Chrispus M. Ngule; Xingcong Ren; Folake A. Oyelami; Oluwafunminiyi Obaleye; Jin-Ming Yang
|